Fresenius Medical Care AG (FMS) Stock Analysis
Verdict: WATCH (do not buy)
Violent Q1 miss derails the recovery narrative, turning a value play into a falling knife until margins and revenue stabilize.
Investment score: 48/100
Analysis as of
Is Fresenius Medical Care AG stock worth reviewing? The TradeMates thesis
Fresenius Medical Care is currently a value trap following a significant Q1 2026 earnings miss that invalidated a short-term recovery trend. While the valuation is historically cheap at 0.7x book value, the lack of revenue growth (1.5%) and high debt levels make it a high-risk entry before a clear floor is established.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Fresenius Medical Care AG opportunities and risks
What speaks for FMS
- Deep Asset Discount
What speaks against FMS
- Dividend Sustainability Risk
Peers and competitors
- FRE.DE
- FME.DE
- 1846.HK
- V3V.DE
- MDQ.HM
Frequently asked questions about Fresenius Medical Care AG (FMS)
Is FMS stock a good investment?
The TradeMates model rates Fresenius Medical Care AG as WATCH (do not buy) with an investment score of 48/100. Fresenius Medical Care is currently a value trap following a significant Q1 2026 earnings miss that invalidated a short-term recovery trend. While the valuation is historically cheap at 0.7x book value, the lack of revenue growth (1.5%) and high debt levels make it a high-risk entry before a clear floor is established. This is algorithmic model output, not personal investment advice.
Is FMS stock a buy?
The TradeMates model verdict for FMS is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.